25 results on '"Rawi, Reda"'
Search Results
2. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination
- Author
-
Andrews, Sarah F., Raab, Julie E., Gorman, Jason, Gillespie, Rebecca A., Cheung, Crystal S. F., Rawi, Reda, Cominsky, Lauren Y., Boyington, Jeffrey C., Creanga, Adrian, Shen, Chen-Hsiang, Harris, Darcy R., Olia, Adam S., Nazzari, Alexandra F., Zhou, Tongqing, Houser, Katherine V., Chen, Grace L., Mascola, John R., Graham, Barney S., Kanekiyo, Masaru, Ledgerwood, Julie E., Kwong, Peter D., and McDermott, Adrian B.
- Abstract
Conserved epitopes on the influenza hemagglutinin (HA) stem are an attractive target for universal vaccine strategies as they elicit broadly neutralizing antibodies. Such antibody responses to stem-specific epitopes have been extensively characterized for HA subtypes H1 and H5 in humans. H2N2 influenza virus circulated 50 years ago and represents a pandemic threat due to the lack of widespread immunity, but, unlike H1 and H5, the H2 HA stem contains Phe45HA2predicted to sterically clash with HA stem-binding antibodies characterized to date. To understand the effect of Phe45HA2, we compared the HA stem-specific B cell response in post hoc analyses of two phase 1 clinical trials, one testing vaccination with an H2 ferritin nanoparticle immunogen (NCT03186781) and one with an inactivated H5N1 vaccine (NCT01086657). In H2-naive individuals, the magnitude of the B cell response was equivalent, but H2-elicited HA stem-binding B cells displayed greater cross-reactivity than those elicited by H5. However, in individuals with childhood H2 exposure, H5-elicited HA stem-binding B cells also displayed high cross-reactivity, suggesting recall of memory B cells formed 50 years ago. Overall, we propose that a one-residue difference on an HA immunogen can alter establishment and expansion of broadly neutralizing memory B cells. These data have implications for stem-based universal influenza vaccination strategies.
- Published
- 2022
- Full Text
- View/download PDF
3. Cryo-EM structures of prefusion SIV envelope trimer
- Author
-
Gorman, Jason, Wang, Chunyan, Mason, Rosemarie D., Nazzari, Alexandra F., Welles, Hugh C., Zhou, Tongqing, Bess, Julian W., Bylund, Tatsiana, Lee, Myungjin, Tsybovsky, Yaroslav, Verardi, Raffaello, Wang, Shuishu, Yang, Yongping, Zhang, Baoshan, Rawi, Reda, Keele, Brandon F., Lifson, Jeffrey D., Liu, Jun, Roederer, Mario, and Kwong, Peter D.
- Abstract
Simian immunodeficiency viruses (SIVs) are lentiviruses that naturally infect non-human primates of African origin and seeded cross-species transmissions of HIV-1 and HIV-2. Here we report prefusion stabilization and cryo-EM structures of soluble envelope (Env) trimers from rhesus macaque SIV (SIVmac) in complex with neutralizing antibodies. These structures provide residue-level definition for SIV-specific disulfide-bonded variable loops (V1 and V2), which we used to delineate variable-loop coverage of the Env trimer. The defined variable loops enabled us to investigate assembled Env-glycan shields throughout SIV, which we found to comprise both N- and O-linked glycans, the latter emanating from V1 inserts, which bound the O-link-specific lectin jacalin. We also investigated in situ SIVmac-Env trimers on virions, determining cryo-electron tomography structures at subnanometer resolutions for an antibody-bound complex and a ligand-free state. Collectively, these structures define the prefusion-closed structure of the SIV-Env trimer and delineate variable-loop and glycan-shielding mechanisms of immune evasion conserved throughout SIV evolution.
- Published
- 2022
- Full Text
- View/download PDF
4. Cholesterol reduction by immunization with a PCSK9 mimic
- Author
-
Zhang, Baoshan, Chuang, Gwo-Yu, Biju, Andrea, Biner, Daniel, Cheng, Jiaxuan, Wang, Yiran, Bao, Saran, Chao, Cara W., Lei, Haotian, Liu, Tracy, Nazzari, Alexandra F., Yang, Yongping, Zhou, Tongqing, Chen, Steven J., Chen, Xuejun, Kong, Wing-Pui, Ou, Li, Parchment, Danealle K., Sarfo, Edward K., Sima, Haomin, Todd, John-Paul, Wang, Shuishu, Woodward, Ruth A., Cheng, Cheng, Rawi, Reda, Mascola, John R., and Kwong, Peter D.
- Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a plasma protein that controls cholesterol homeostasis. Here, we design a human PCSK9 mimic, named HIT01, with no consecutive 9-residue stretch in common with any human protein as a potential heart attack vaccine. Murine immunizations with HIT01 reduce low-density lipoprotein (LDL) and cholesterol levels by 40% and 30%, respectively. Immunization of cynomolgus macaques with HIT01-K21Q-R218E, a cleavage-resistant variant, elicits high titers PCSK9-directed antibody responses and significantly reduces serum levels of cholesterol 2 weeks after each immunization. However, HIT01 immunizations also increase serum PCSK9 levels by up to 10-fold, likely due to PCSK9-binding antibodies altering the half-life of PCSK9. While vaccination with a PCSK9 mimic can induce antibodies that block interactions of PCSK9 with the LDL receptor, PCSK9-binding antibodies appear to alter homeostatic levels of PCSK9, thereby confounding its vaccine impact. Our results nevertheless suggest a mechanism for increasing the half-life of soluble regulatory factors by vaccination.
- Published
- 2024
- Full Text
- View/download PDF
5. CRISPro: An Automated Pipeline for Protein Conformation Stabilization by Proline.
- Author
-
Rawi, Reda, Shen, Chen-Hsiang, Kwong, Peter D., and Chuang, Gwo-Yu
- Published
- 2018
- Full Text
- View/download PDF
6. Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
- Author
-
Kwon, Young D., Pegu, Amarendra, Yang, Eun Sung, Zhang, Baoshan, Bender, Michael F., Asokan, Mangaiarkarasi, Liu, Qingbo, McKee, Krisha, Lin, Bob C., Liu, Tracy, Louder, Mark K., Rawi, Reda, Reveiz, Mateo, Schaub, Andrew J., Shen, Chen-Hsiang, Doria-Rose, Nicole A., Lusso, Paolo, Mascola, John R., and Kwong, Peter D.
- Abstract
ABSTRACTThe amino-acid composition of the immunoglobulin variable region has been observed to impact antibody pharmacokinetics (PK). Here, we sought to improve the PK of the broad HIV−1-neutralizing VRC01-class antibodies, VRC07-523LS and N6LS, by reducing the net positive charge in their variable domains. We used a structure-guided approach to generate a panel of antibody variants incorporating select Arg or Lys substituted to Asp, Gln, Glu, or Ser. The engineered variants exhibited reduced affinity to heparin, reduced polyreactivity, and improved PK in human FcRn-transgenic mice. One variant, VRC07-523LS.v34, with three charge substitutions, had an observed in vivohalf-life and an estimated human half-life of 10.8 and 60 days, respectively (versus 5.4 and 38 days for VRC07-523LS) and retained functionality, neutralizing 92% of a 208-strain panel at a geometric mean IC80<1 µg/mL. Another variant, N6LS.C49, with two charge substitutions, had an observed in vivohalf-life and an estimated human half-life of 14.5 and 80 days (versus 9.0 and 44 days for N6LS) and neutralized ~80% of 208 strains at a geometric mean IC80<1 µg/mL. Since Arg and Lys residues are prevalent in human antibodies, we propose substitution of select Arg or Lys with Asp, Gln, Glu, or Ser in the framework region as a general means to improve PK of therapeutic antibodies.
- Published
- 2023
- Full Text
- View/download PDF
7. Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
- Author
-
Zhang, Baoshan, Gorman, Jason, Kwon, Young D., Pegu, Amarendra, Chao, Cara W., Liu, Tracy, Asokan, Mangaiarkarasi, Bender, Michael F., Bylund, Tatsiana, Damron, Leland, Gollapudi, Deepika, Lei, Paula, Li, Yile, Liu, Cuiping, Louder, Mark K., McKee, Krisha, Olia, Adam S., Rawi, Reda, Schön, Arne, Wang, Shuishu, Yang, Eun Sung, Yang, Yongping, Carlton, Kevin, Doria-Rose, Nicole A., Shapiro, Lawrence, Seaman, Michael S., Mascola, John R., and Kwong, Peter D.
- Abstract
ABSTRACTAntibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS, an optimized version of CAP256-VRC26.25 currently under clinical evaluation, to the llama nanobody J3, which has broad CD4-binding site-directed neutralization. The J3-linked bispecific antibody exhibited improved breadth and potency over both J3 and CAP256V2LS, indicative of synergistic neutralization. The cryo-EM structure of the bispecific antibody in complex with a prefusion-closed Env trimer revealed simultaneous binding of J3 and CAP256V2LS. We further optimized the pharmacokinetics of the bispecific antibody by reducing the net positive charge of J3. The optimized bispecific antibody, which we named CAP256.J3LS, had a half-life similar to CAP256V2LS in human FcRn knock-in mice and exhibited suitable auto-reactivity, manufacturability, and biophysical risk. CAP256.J3LS neutralized over 97% of a multiclade 208-strain panel (geometric mean concentration for 80% inhibition (IC80) 0.079 μg/ml) and 100% of a 100-virus clade C panel (geometric mean IC80of 0.05 μg/ml), suggesting its anti-HIV utility especially in regions where clade C dominates.
- Published
- 2023
- Full Text
- View/download PDF
8. CRISPro: An Automated Pipeline for Protein Conformation Stabilization by Proline
- Author
-
Rawi, Reda, Shen, Chen-Hsiang, Kwong, Peter D., and Chuang, Gwo-Yu
- Abstract
Recent studies have shown that the yield, antigenicity, and immunogenicity of an immunogen can be enhanced by stabilizing it into a specific conformation. Such stabilization often involves the engineering of proline mutations at residue positions where a proline is structurally compatible with the target conformation but not with an alternative conformation. However, there is no publicly available tool that can design proline mutations for this purpose automatically. Here we implemented an automated tool, CRISPro, that inputs structural coordinates of the target conformation and/or an alternative conformation and outputs a list of residue positions where proline mutations are predicted to stabilize the target conformation based on compatibility of phi–psi angles, secondary structure, and steric constraints. Thus, CRISPro can be used to engineer immunogens into specific conformation and to design serologic probes, capable of isolating antibodies that recognize a target shape.
- Published
- 2018
- Full Text
- View/download PDF
9. HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide
- Author
-
Wang, Shuishu, Matassoli, Flavio, Zhang, Baoshan, Liu, Tracy, Shen, Chen-Hsiang, Bylund, Tatsiana, Johnston, Timothy, Henry, Amy R., Teng, I-Ting, Tripathi, Prabhanshu, Becker, Jordan E., Changela, Anita, Chaudhary, Ridhi, Cheng, Cheng, Gaudinski, Martin, Gorman, Jason, Harris, Darcy R., Lee, Myungjin, Morano, Nicholas C., Novik, Laura, O’Dell, Sijy, Olia, Adam S., Parchment, Danealle K., Rawi, Reda, Roberts-Torres, Jesmine, Stephens, Tyler, Tsybovsky, Yaroslav, Wang, Danyi, Van Wazer, David J., Zhou, Tongqing, Doria-Rose, Nicole A., Koup, Richard A., Shapiro, Lawrence, Douek, Daniel C., McDermott, Adrian B., and Kwong, Peter D.
- Abstract
Elicitation of antibodies that neutralize the tier-2 neutralization-resistant isolates that typify HIV-1 transmission has been a long-sought goal. Success with prefusion-stabilized envelope trimers eliciting autologous neutralizing antibodies has been reported in multiple vaccine-test species, though not in humans. To investigate elicitation of HIV-1 neutralizing antibodies in humans, here, we analyze B cells from a phase I clinical trial of the “DS-SOSIP”-stabilized envelope trimer from strain BG505, identifying two antibodies, N751-2C06.01 and N751-2C09.01 (named for donor-lineage.clone), that neutralize the autologous tier-2 strain, BG505. Though derived from distinct lineages, these antibodies form a reproducible antibody class that targets the HIV-1 fusion peptide. Both antibodies are highly strain specific, which we attribute to their partial recognition of a BG505-specific glycan hole and to their binding requirements for a few BG505-specific residues. Prefusion-stabilized envelope trimers can thus elicit autologous tier-2 neutralizing antibodies in humans, with initially identified neutralizing antibodies recognizing the fusion-peptide site of vulnerability.
- Published
- 2023
- Full Text
- View/download PDF
10. Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silicodesign
- Author
-
Holt, Graham T., Gorman, Jason, Wang, Siyu, Lowegard, Anna U., Zhang, Baoshan, Liu, Tracy, Lin, Bob C., Louder, Mark K., Frenkel, Marcel S., McKee, Krisha, O’Dell, Sijy, Rawi, Reda, Shen, Chen-Hsiang, Doria-Rose, Nicole A., Kwong, Peter D., and Donald, Bruce R.
- Abstract
Broadly neutralizing antibodies (bNAbs) against HIV can reduce viral transmission in humans, but an effective therapeutic will require unusually high breadth and potency of neutralization. We employ the OSPREY computational protein design software to engineer variants of two apex-directed bNAbs, PGT145 and PG9RSH, resulting in increases in potency of over 100-fold against some viruses. The top designed variants improve neutralization breadth from 39% to 54% at clinically relevant concentrations (IC80 < 1 μg/mL) and improve median potency (IC80) by up to 4-fold over a cross-clade panel of 208 strains. To investigate the mechanisms of improvement, we determine cryoelectron microscopy structures of each variant in complex with the HIV envelope trimer. Surprisingly, we find the largest increases in breadth to be a result of optimizing side-chain interactions with highly variable epitope residues. These results provide insight into mechanisms of neutralization breadth and inform strategies for antibody design and improvement.
- Published
- 2023
- Full Text
- View/download PDF
11. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
- Author
-
Xu, Kai, Acharya, Priyamvada, Kong, Rui, Cheng, Cheng, Chuang, Gwo-Yu, Liu, Kevin, Louder, Mark K., O’Dell, Sijy, Rawi, Reda, Sastry, Mallika, Shen, Chen-Hsiang, Zhang, Baoshan, Zhou, Tongqing, Asokan, Mangaiarkarasi, Bailer, Robert T., Chambers, Michael, Chen, Xuejun, Choi, Chang W., Dandey, Venkata P., Doria-Rose, Nicole A., Druz, Aliaksandr, Eng, Edward T., Farney, S. Katie, Foulds, Kathryn E., Geng, Hui, Georgiev, Ivelin S., Gorman, Jason, Hill, Kurt R., Jafari, Alexander J., Kwon, Young D., Lai, Yen-Ting, Lemmin, Thomas, McKee, Krisha, Ohr, Tiffany Y., Ou, Li, Peng, Dongjun, Rowshan, Ariana P., Sheng, Zizhang, Todd, John-Paul, Tsybovsky, Yaroslav, Viox, Elise G., Wang, Yiran, Wei, Hui, Yang, Yongping, Zhou, Amy F., Chen, Rui, Yang, Lu, Scorpio, Diana G., McDermott, Adrian B., Shapiro, Lawrence, Carragher, Bridget, Potter, Clinton S., Mascola, John R., and Kwong, Peter D.
- Abstract
A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune response to exposed N-terminal residues of the fusion peptide, a critical component of the viral entry machinery and the epitope of antibodies elicited by HIV-1 infection, through immunization with fusion peptide-coupled carriers and prefusion stabilized envelope trimers, induces cross-clade neutralizing responses. In mice, these immunogens elicited monoclonal antibodies capable of neutralizing up to 31% of a cross-clade panel of 208 HIV-1 strains. Crystal and cryoelectron microscopy structures of these antibodies revealed fusion peptide conformational diversity as a molecular explanation for the cross-clade neutralization. Immunization of guinea pigs and rhesus macaques induced similarly broad fusion peptide-directed neutralizing responses, suggesting translatability. The N terminus of the HIV-1 fusion peptide is thus a promising target of vaccine efforts aimed at eliciting broadly neutralizing antibodies.
- Published
- 2018
- Full Text
- View/download PDF
12. Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody
- Author
-
Kwon, Young D., Chuang, Gwo-Yu, Zhang, Baoshan, Bailer, Robert T., Doria-Rose, Nicole A., Gindin, Tatyana S., Lin, Bob, Louder, Mark K., McKee, Krisha, O’Dell, Sijy, Pegu, Amarendra, Schmidt, Stephen D., Asokan, Mangaiarkarasi, Chen, Xuejun, Choe, Misook, Georgiev, Ivelin S., Jin, Vivian, Pancera, Marie, Rawi, Reda, Wang, Keyun, Chaudhuri, Rajoshi, Kueltzo, Lisa A., Manceva, Slobodanka D., Todd, John-Paul, Scorpio, Diana G., Kim, Mikyung, Reinherz, Ellis L., Wagh, Kshitij, Korber, Bette M., Connors, Mark, Shapiro, Lawrence, Mascola, John R., and Kwong, Peter D.
- Abstract
Highly effective HIV-1-neutralizing antibodies could have utility in the prevention or treatment of HIV-1 infection. To improve the potency of 10E8, an antibody capable of near pan-HIV-1 neutralization, we engineered 10E8-surface mutants and screened for improved neutralization. Variants with the largest functional enhancements involved the addition of hydrophobic or positively charged residues, which were positioned to interact with viral membrane lipids or viral glycan-sialic acids, respectively. In both cases, the site of improvement was spatially separated from the region of antibody mediating molecular contact with the protein component of the antigen, thereby improving peripheral semi-specific interactions while maintaining unmodified dominant contacts responsible for broad recognition. The optimized 10E8 antibody, with mutations to phenylalanine and arginine, retained the extraordinary breadth of 10E8 but with ∼10-fold increased potency. We propose surface-matrix screening as a general method to improve antibodies, with improved semi-specific interactions between antibody and antigen enabling increased potency without compromising breadth.
- Published
- 2018
- Full Text
- View/download PDF
13. Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains
- Author
-
Joyce, M. Gordon, Georgiev, Ivelin S., Yang, Yongping, Druz, Aliaksandr, Geng, Hui, Chuang, Gwo-Yu, Kwon, Young Do, Pancera, Marie, Rawi, Reda, Sastry, Mallika, Stewart-Jones, Guillaume B.E., Zheng, Angela, Zhou, Tongqing, Choe, Misook, Van Galen, Joseph G., Chen, Rita E., Lees, Christopher R., Narpala, Sandeep, Chambers, Michael, Tsybovsky, Yaroslav, Baxa, Ulrich, McDermott, Adrian B., Mascola, John R., and Kwong, Peter D.
- Abstract
The elicitation of autologous neutralizing responses by immunization with HIV-1 envelope (Env) trimers conformationally stabilized in a prefusion closed state has generated considerable interest in the HIV-1 vaccine field. However, soluble prefusion closed Env trimers have been produced from only a handful of HIV-1 strains, limiting their utility as vaccine antigens and B cell probes. Here, we report the engineering from 81 HIV-1 strains of soluble, fully cleaved, prefusion Env trimers with appropriate antigenicity. We used a 96-well expression-screening format to assess the ability of artificial disulfides and Ile559Pro substitution (DS-SOSIP) to produce soluble cleaved-Env trimers; from 180 Env strains, 20 yielded prefusion closed trimers. We also created chimeras, by utilizing structure-based design to incorporate select regions from the well-behaved BG505 strain; from 180 Env strains, 78 DS-SOSIP-stabilized chimeras, including 61 additional strains, yielded prefusion closed trimers. Structure-based design thus enables the production of prefusion closed HIV-1-Env trimers from dozens of diverse strains.
- Published
- 2017
- Full Text
- View/download PDF
14. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529
- Author
-
Pancera, Marie, Lai, Yen-Ting, Bylund, Tatsiana, Druz, Aliaksandr, Narpala, Sandeep, O'Dell, Sijy, Schön, Arne, Bailer, Robert T, Chuang, Gwo-Yu, Geng, Hui, Louder, Mark K, Rawi, Reda, Soumana, Djade I, Finzi, Andrés, Herschhorn, Alon, Madani, Navid, Sodroski, Joseph, Freire, Ernesto, Langley, David R, Mascola, John R, McDermott, Adrian B, and Kwong, Peter D
- Abstract
The HIV-1 envelope (Env) spike is a conformational machine that transitions between prefusion (closed, CD4- and CCR5-bound) and postfusion states to facilitate HIV-1 entry into cells. Although the prefusion closed conformation is a potential target for inhibition, development of small-molecule leads has been stymied by difficulties in obtaining structural information. Here, we report crystal structures at 3.8-Å resolution of an HIV-1-Env trimer with BMS-378806 and a derivative BMS-626529 for which a prodrug version is currently in Phase III clinical trials. Both lead candidates recognized an induced binding pocket that was mostly excluded from solvent and comprised of Env elements from a conserved helix and the β20–21 hairpin. In both structures, the β20–21 region assumed a conformation distinct from prefusion-closed and CD4-bound states. Together with biophysical and antigenicity characterizations, the structures illuminate the allosteric and competitive mechanisms by which these small-molecule leads inhibit CD4-induced structural changes in Env.
- Published
- 2017
- Full Text
- View/download PDF
15. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation
- Author
-
Zhou, Tongqing, Doria-Rose, Nicole A., Cheng, Cheng, Stewart-Jones, Guillaume B.E., Chuang, Gwo-Yu, Chambers, Michael, Druz, Aliaksandr, Geng, Hui, McKee, Krisha, Kwon, Young Do, O’Dell, Sijy, Sastry, Mallika, Schmidt, Stephen D., Xu, Kai, Chen, Lei, Chen, Rita E., Louder, Mark K., Pancera, Marie, Wanninger, Timothy G., Zhang, Baoshan, Zheng, Anqi, Farney, S. Katie, Foulds, Kathryn E., Georgiev, Ivelin S., Joyce, M. Gordon, Lemmin, Thomas, Narpala, Sandeep, Rawi, Reda, Soto, Cinque, Todd, John-Paul, Shen, Chen-Hsiang, Tsybovsky, Yaroslav, Yang, Yongping, Zhao, Peng, Haynes, Barton F., Stamatatos, Leonidas, Tiemeyer, Michael, Wells, Lance, Scorpio, Diana G., Shapiro, Lawrence, McDermott, Adrian B., Mascola, John R., and Kwong, Peter D.
- Abstract
While the HIV-1-glycan shield is known to shelter Env from the humoral immune response, its quantitative impact on antibody elicitation has been unclear. Here, we use targeted deglycosylation to measure the impact of the glycan shield on elicitation of antibodies against the CD4 supersite. We engineered diverse Env trimers with select glycans removed proximal to the CD4 supersite, characterized their structures and glycosylation, and immunized guinea pigs and rhesus macaques. Immunizations yielded little neutralization against wild-type viruses but potent CD4-supersite neutralization (titers 1: >1,000,000 against four-glycan-deleted autologous viruses with over 90% breadth against four-glycan-deleted heterologous strains exhibiting tier 2 neutralization character). To a first approximation, the immunogenicity of the glycan-shielded protein surface was negligible, with Env-elicited neutralization (ID50) proportional to the exponential of the protein-surface area accessible to antibody. Based on these high titers and exponential relationship, we propose site-selective deglycosylated trimers as priming immunogens to increase the frequency of site-targeting antibodies.
- Published
- 2017
- Full Text
- View/download PDF
16. Highly protective antimalarial antibodies via precision library generation and yeast display screening
- Author
-
Banach, Bailey B., Tripathi, Prabhanshu, Da Silva Pereira, Lais, Gorman, Jason, Nguyen, Thuy Duong, Dillon, Marlon, Fahad, Ahmed S., Kiyuka, Patience K., Madan, Bharat, Wolfe, Jacy R., Bonilla, Brian, Flynn, Barbara, Francica, Joseph R., Hurlburt, Nicholas K., Kisalu, Neville K., Liu, Tracy, Ou, Li, Rawi, Reda, Schön, Arne, Shen, Chen-Hsiang, Teng, I-Ting, Zhang, Baoshan, Pancera, Marie, Idris, Azza H., Seder, Robert A., Kwong, Peter D., and DeKosky, Brandon J.
- Abstract
The monoclonal antibody CIS43 targets the Plasmodium falciparum circumsporozoite protein (PfCSP) and prevents malaria infection in humans for up to 9 mo following a single intravenous administration. To enhance the potency and clinical utility of CIS43, we used iterative site-saturation mutagenesis and DNA shuffling to screen precise gene-variant yeast display libraries for improved PfCSP antigen recognition. We identified several mutations that improved recognition, predominately in framework regions, and combined these to produce a panel of antibody variants. The most improved antibody, CIS43_Var10, had three mutations and showed approximately sixfold enhanced protective potency in vivo compared to CIS43. Co-crystal and cryo-electron microscopy structures of CIS43_Var10 with the peptide epitope or with PfCSP, respectively, revealed functional roles for each of these mutations. The unbiased site-directed mutagenesis and screening pipeline described here represent a powerful approach to enhance protective potency and to enable broader clinical use of antimalarial antibodies.
- Published
- 2022
- Full Text
- View/download PDF
17. C3-Symmetric Aromatic Core of Griffithsin Is Essential for Potent Anti-HIV Activity
- Author
-
Sun, Jiadong, Zhao, Gengxiang, Bylund, Tatsiana, Lee, Myungjin, Adibhatla, Srikar, Kwong, Peter D., Chuang, Gwo-Yu, Rawi, Reda, and Bewley, Carole A.
- Abstract
Lectins, carbohydrate-binding proteins of nonimmune origin, bind to carbohydrates and glycan shields present on the surfaces of cells and viral spike proteins. Lectins thus hold great promise as therapeutic and diagnostic proteins, exemplified by their potent antiviral activities and the desire to engineer synthetic carbohydrate receptors based on lectin recognition principles. Here, we describe a new carbohydrate-binding architectural motif─namely, a C3-symmetric tyrosine-based aromatic core, present in the therapeutic lectin griffithsin (GRFT). By using structure-based amino acid substitutions, X-ray crystallography, molecular dynamics (MD) simulations, and HIV-1 neutralization assays, we show that this core is critical for potent (pM) antiviral activity and nanomolar binding to the glycan shield largely consisting of high mannose glycans. Crystal structures and MD simulations show that CH−π interactions stabilize the aromatic cluster to maintain the three pseudo-symmetric carbohydrate-binding sites, nonaromatic amino acid substitutions (Tyr to Ala) abrogate antiviral activity, and increasing the aromatic CH−π edge-to-centroid interface via a Tyr to Trp substitution yields a GRFT variant with improved potency and increased residence time of Man-9 observed in MD simulations. NMR titrations of a Tyr-to-Ala variant indicate that disruption of the aromatic prevents the intermolecular crosslinking between two equivalents of Man-9 and one carbohydrate-binding face observed in wild-type GRFT and known to be critical for picomolar potency of this lectin. This C3-symmetric aromatic core defines a new recognition motif for the design of carbohydrate receptors and suggests principles for engineering known lectins to have increased affinity and stability.
- Published
- 2022
- Full Text
- View/download PDF
18. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.
- Author
-
Cerutti, Gabriele, Guo, Yicheng, Zhou, Tongqing, Gorman, Jason, Lee, Myungjin, Rapp, Micah, Reddem, Eswar R., Yu, Jian, Bahna, Fabiana, Bimela, Jude, Huang, Yaoxing, Katsamba, Phinikoula S., Liu, Lihong, Nair, Manoj S., Rawi, Reda, Olia, Adam S., Wang, Pengfei, Zhang, Baoshan, Chuang, Gwo-Yu, and Ho, David D.
- Abstract
Numerous antibodies that neutralize SARS-CoV-2 have been identified, and these generally target either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral spike. While RBD-directed antibodies have been extensively studied, far less is known about NTD-directed antibodies. Here, we report cryo-EM and crystal structures for seven potent NTD-directed neutralizing antibodies in complex with spike or isolated NTD. These structures defined several antibody classes, with at least one observed in multiple convalescent donors. The structures revealed that all seven antibodies target a common surface, bordered by glycans N 17, N 74, N 122, and N 149. This site—formed primarily by a mobile β-hairpin and several flexible loops—was highly electropositive, located at the periphery of the spike, and the largest glycan-free surface of NTD facing away from the viral membrane. Thus, in contrast to neutralizing RBD-directed antibodies that recognize multiple non-overlapping epitopes, potent NTD-directed neutralizing antibodies appear to target a single supersite. [Display omitted] • Structures of seven NTD-directed neutralizing antibody complexes with spike or NTD • Structures define distinct recognition classes, one observed in multiple donors • Supersite is glycan free, electropositive, with mobile β-hairpin and flexible loops • Most potent NTD-directed neutralizing antibodies may target this supersite Cerutti et al. report structural analysis of seven potent neutralizing antibodies targeting the N-terminal domain of SARS-CoV-2 spike. All antibodies recognize a common glycan-free, electropositive surface comprised of a mobile β-hairpin and flexible loops. While RBD-directed antibodies recognize non-overlapping epitopes, these findings indicate that NTD-directed antibodies predominantly target a single supersite. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
- Author
-
Cottrell, Christopher A., Manne, Kartik, Kong, Rui, Wang, Shuishu, Zhou, Tongqing, Chuang, Gwo-Yu, Edwards, Robert J., Henderson, Rory, Janowska, Katarzyna, Kopp, Megan, Lin, Bob C., Louder, Mark K., Olia, Adam S., Rawi, Reda, Shen, Chen-Hsiang, Taft, Justin D., Torres, Jonathan L., Wu, Nelson R., Zhang, Baoshan, Doria-Rose, Nicole A., Cohen, Myron S., Haynes, Barton F., Shapiro, Lawrence, Ward, Andrew B., Acharya, Priyamvada, Mascola, John R., and Kwong, Peter D.
- Abstract
Recognition of N-linked glycan at residue N276 (glycan276) at the periphery of the CD4-binding site (CD4bs) on the HIV-envelope trimer is a formidable challenge for many CD4bs-directed antibodies. To understand how this glycan can be recognized, here we isolate two lineages of glycan276-dependent CD4bs antibodies. Antibody CH540-VRC40.01 (named for donor-lineage.clone) neutralizes 81% of a panel of 208 diverse strains, while antibody CH314-VRC33.01 neutralizes 45%. Cryo-electron microscopy (cryo-EM) structures of these two antibodies and 179NC75, a previously identified glycan276-dependent CD4bs antibody, in complex with HIV-envelope trimer reveal substantially different modes of glycan276 recognition. Despite these differences, binding of glycan276-dependent antibodies maintains a glycan276 conformation similar to that observed in the absence of glycan276-binding antibodies. By contrast, glycan276-independent CD4bs antibodies, such as VRC01, displace glycan276 upon binding. These results provide a foundation for understanding antibody recognition of glycan276 and suggest its presence may be crucial for priming immunogens seeking to initiate broad CD4bs recognition.
- Published
- 2021
- Full Text
- View/download PDF
20. Blocking α4β7integrin delays viral rebound in SHIVSF162P3-infected macaques treated with anti-HIV broadly neutralizing antibodies
- Author
-
Frank, Ines, Cigoli, Mariasole, Arif, Muhammad S., Fahlberg, Marissa D., Maldonado, Stephanie, Calenda, Giulia, Pegu, Amarendra, Yang, Eun Sung, Rawi, Reda, Chuang, Gwo-Yu, Geng, Hui, Liu, Cuiping, Zhou, Tongqing, Kwong, Peter D., Arthos, James, Cicala, Claudia, Grasperge, Brooke F., Blanchard, James L., Gettie, Agegnehu, Fennessey, Christine M., Keele, Brandon F., Vaccari, Monica, Hope, Thomas J., Fauci, Anthony S., Mascola, John R., and Martinelli, Elena
- Abstract
Description
- Published
- 2021
- Full Text
- View/download PDF
21. VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.
- Author
-
Shen, Chen-Hsiang, DeKosky, Brandon J., Guo, Yicheng, Xu, Kai, Gu, Ying, Kilam, Divya, Ko, Sung Hee, Kong, Rui, Liu, Kevin, Louder, Mark K., Ou, Li, Zhang, Baoshan, Chao, Cara W., Corcoran, Martin M., Feng, Eric, Huang, Jesse, Normandin, Erica, O'Dell, Sijy, Ransier, Amy, and Rawi, Reda
- Abstract
Rare mutations have been proposed to restrict the development of broadly neutralizing antibodies against HIV-1, but this has not been explicitly demonstrated. We hypothesized that such rare mutations might be identified by comparing broadly neutralizing and non-broadly neutralizing branches of an antibody-developmental tree. Because sequences of antibodies isolated from the fusion peptide (FP)-targeting VRC34-antibody lineage suggested it might be suitable for such rare mutation analysis, we carried out next-generation sequencing (NGS) on B cell transcripts from donor N123, the source of the VRC34 lineage, and functionally and structurally characterized inferred intermediates along broadly neutralizing and poorly neutralizing developmental branches. The broadly neutralizing VRC34.01 branch required the rare heavy-chain mutation Y33P to bind FP, whereas the early bifurcated VRC34.05 branch did not require this rare mutation and evolved less breadth. Our results demonstrate how a required rare mutation can restrict development and shape the maturation of a broad HIV-1-neutralizing antibody lineage. • Maturation of VRC34 lineage bifurcates early along VRC34.01 and VRC34.05 branches • VRC34.01 branch requires the rare mutation Y33P HC to achieve broad neutralization • VRC34.05 branch utilizes Y33 to bind FP and does not achieve broad neutralization • An early rare mutation shapes VRC34-lineage development and neutralization breadth Rare mutations have been hypothesized to control the development of broadly neutralizing antibody lineages. However, this has not been explicitly demonstrated. Shen et al. show that a rare mutation, present only in the neutralization branch of the VRC34-antibody lineage, both restricts and shapes the maturation of this lineage. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains
- Author
-
Rawi, Reda, Rutten, Lucy, Lai, Yen-Ting, Olia, Adam S., Blokland, Sven, Juraszek, Jarek, Shen, Chen-Hsiang, Tsybovsky, Yaroslav, Verardi, Raffaello, Yang, Yongping, Zhang, Baoshan, Zhou, Tongqing, Chuang, Gwo-Yu, Kwong, Peter D., and Langedijk, Johannes P.M.
- Abstract
Soluble envelope (Env) trimers, stabilized in a prefusion-closed conformation, can elicit neutralizing responses against HIV-1 strains closely related to the immunizing trimer. However, to date such stabilization has succeeded with only a limited number of HIV-1 strains. To address this issue, here we develop ADROITrimer, an automated procedure involving structure-based stabilization and consensus repair, and generate “RnS-DS-SOSIP”-stabilized Envs from 180 diverse Env sequences. The vast majority of these RnS-DS-SOSIP Envs fold into prefusion-closed conformations as judged by antigenic analysis and size exclusion chromatography. Additionally, representative strains from clades AE, B, and C are stabilized in prefusion-closed conformations as shown by negative-stain electron microscopy, and the crystal structure of a clade A strain MI369.A5 Env trimer provides 3.5 Å resolution detail into stabilization and repair mutations. The automated procedure reported herein that yields well-behaved, soluble, prefusion-closed Env trimers from a majority of HIV-1 strains could have substantial impact on the development of an HIV-1 vaccine.
- Published
- 2020
- Full Text
- View/download PDF
23. Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation
- Author
-
Cheung, Crystal Sao-Fong, Fruehwirth, Alexander, Paparoditis, Philipp Carl Georg, Shen, Chen-Hsiang, Foglierini, Mathilde, Joyce, M. Gordon, Leung, Kwanyee, Piccoli, Luca, Rawi, Reda, Silacci-Fregni, Chiara, Tsybovsky, Yaroslav, Verardi, Raffaello, Wang, Lingshu, Wang, Shuishu, Yang, Eun Sung, Zhang, Baoshan, Zhang, Yi, Chuang, Gwo-Yu, Corti, Davide, Mascola, John R., Shapiro, Lawrence, Kwong, Peter D., Lanzavecchia, Antonio, and Zhou, Tongqing
- Abstract
Multidonor antibodies are of interest for vaccine design because they can in principle be elicited in the general population by a common set of immunogens. For influenza, multidonor antibodies have been observed against the hemagglutinin (HA) stem, but not the immunodominant HA head. Here, we identify and characterize a multidonor antibody class (LPAF-a class) targeting the HA head. This class exhibits potent viral entry inhibition against H1N1 A/California/04/2009 (CA09) virus. LPAF-a class antibodies derive from the HV2-70 gene and contain a “Tyr-Gly-Asp”-motif, which occludes the HA-sialic acid binding site as revealed by a co-crystal structure with HA. Both germline-reverted and mature LPAF antibodies potently neutralize CA09 virus and have nanomolar affinities for CA09 HA. Moreover, increased frequencies for LPFA-a class antibodies are observed in humans after a single vaccination. Overall, this work highlights the identification of a multidonor class of head-directed influenza-neutralizing antibodies and delineates the mechanism of their recurrent elicitation in humans.
- Published
- 2020
- Full Text
- View/download PDF
24. Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition
- Author
-
Gorman, Jason, Chuang, Gwo-Yu, Lai, Yen-Ting, Shen, Chen-Hsiang, Boyington, Jeffrey C., Druz, Aliaksandr, Geng, Hui, Louder, Mark K., McKee, Krisha, Rawi, Reda, Verardi, Raffaello, Yang, Yongping, Zhang, Baoshan, Doria-Rose, Nicole A., Lin, Bob, Moore, Penny L., Morris, Lynn, Shapiro, Lawrence, Mascola, John R., and Kwong, Peter D.
- Abstract
Antibodies targeting the V1V2 apex of the HIV-1 envelope (Env) trimer comprise one of the most commonly elicited categories of broadly neutralizing antibodies. Structures of these antibodies indicate diverse modes of Env recognition typified by antibodies of the PG9 class and the PGT145 class. The mode of recognition, however, has been unclear for the most potent of the V1V2 apex-targeting antibodies, CAP256-VRC26.25 (named for donor-lineage.clone and referred to hereafter as VRC26.25). Here, we determine the cryoelectron microscopy structure at 3.7 Å resolution of the antigen-binding fragment of VRC26.25 in complex with the Env trimer thought to have initiated the lineage. The 36-residue protruding loop of VRC26.25 displays recognition incorporating both strand-C interactions similar to the PG9 class and V1V2 apex insertion similar to the PGT145 class. Structural elements of separate antibody classes can thus intermingle to form a “combined” class, which in this case yields an antibody of extraordinary potency.
- Published
- 2020
- Full Text
- View/download PDF
25. Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth
- Author
-
Wagh, Kshitij, Kreider, Edward F., Li, Yingying, Barbian, Hannah J., Learn, Gerald H., Giorgi, Elena, Hraber, Peter T., Decker, Timothy G., Smith, Andrew G., Gondim, Marcos V., Gillis, Lindsey, Wandzilak, Jamie, Chuang, Gwo-Yu, Rawi, Reda, Cai, Fangping, Pellegrino, Pierre, Williams, Ian, Overbaugh, Julie, Gao, Feng, Kwong, Peter D., Haynes, Barton F., Shaw, George M., Borrow, Persephone, Seaman, Michael S., Hahn, Beatrice H., and Korber, Bette
- Abstract
Densely arranged N-linked glycans shield the HIV-1 envelope (Env) trimer from antibody recognition. Strain-specific breaches in this shield (glycan holes) can be targets of vaccine-induced neutralizing antibodies that lack breadth. To understand the interplay between glycan holes and neutralization breadth in HIV-1 infection, we developed a sequence- and structure-based approach to identify glycan holes for individual Env sequences that are shielded in most M-group viruses. Applying this approach to 12 longitudinally followed individuals, we found that transmitted viruses with more intact glycan shields correlated with development of greater neutralization breadth. Within 2 years, glycan acquisition filled most glycan holes present at transmission, indicating escape from hole-targeting neutralizing antibodies. Glycan hole filling generally preceded the time to first detectable breadth, although time intervals varied across hosts. Thus, completely glycan-shielded viruses were associated with accelerated neutralization breadth development, suggesting that Env immunogens with intact glycan shields may be preferred components of AIDS vaccines.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.